 Eidos Therapeutics NASDAQ:EIDX was upgraded by analysts at BidaskClub from a sell rating to a hold rating in a research report issued on Saturday, BidAskClub reports. Several other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Eidos Therapeutics from a buy rating to a hold rating in a research ... 